DOCSLIB.ORG

Over-The-Counter and Natural Remedies for Onychomycosis: Do They Really Work?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Over-The-Counter and Natural Remedies for Onychomycosis: Do They Really Work? Over-the-counter and Natural Remedies for Onychomycosis: Do They Really Work? Pierre Halteh; Richard K. Scher, MD; Shari R. Lipner, MD, PhD PRACTICE POINTS • Natural remedies, including tea tree oil, natural topical cough suppressants, natural coniferous resin lacquer, Ageratina pichinchensis extract, and ozonized sunflower oil, have shown antifungal activities in in vitro studies. • Some of these products have efficacy and appear to be safe in clinical studies. • Larger randomized clinical trials demonstrating efficacy are required beforecopy we can recommend these products to our patients. not Onychomycosis is a fungal infection of the nail unit effective, and cost-effective options for onychomy- that may lead to dystrophy and disfigurement over cosis therapy, there has been a renewed interest time. It accounts for up to 50% of all nail condi-Doin natural and over-the-counter (OTC) alternatives. tions, with toenails affected more commonly than This review will synthesize the laboratory data, fingernails. Onychomycosis may affect quality of known antifungal mechanisms, and clinical studies life and increase the prevalence and severity of assessing the efficacy of OTC and natural prod- foot ulcers in patients with diabetes. Available ucts for onychomycosis treatment. oral agents approved by the US Food and Drug Cutis. 2016;98:E16-E25. Administration (FDA) for the treatment of ony- chomycosis include terbinafine and itraconazole, which have demonstratedCUTIS good efficacy but are nychomycosis is a fungal infection of the associated with the risk of systemic side effects nail unit by dermatophytes, yeasts, and non- and drug-drug interactions. Topical medications Odermatophyte molds. It is characterized by that are FDA approved for onychomycosis include a white or yellow discoloration of the nail plate; ciclopirox, efinaconazole, and tavaborole. These hyperkeratosis of the nail bed; distal detachment therapies generally have incomplete efficacy com- of the nail plate from its bed (onycholysis); and pared to systemic agents as well as long treatment nail plate dystrophy, including thickening, crum- courses and possible local side effects such as bling, and ridging. Onychomycosis is an important erythema and/or blisters. Given the need for safe, problem, representing 30% of all superficial fungal infections and an estimated 50% of all nail diseases.1 Mr. Halteh is from Weill Cornell Medical College, Qatar, Ar-Rayyan. Reported prevalence rates of onychomycosis in the Drs. Scher and Lipner are from the Department of Dermatology, United States and worldwide are varied, but the mean Weill Cornell Medical College, New York, New York. prevalence based on population-based studies in Mr. Halteh reports no conflict of interest. Dr. Scher is a consultant for Europe and North America is estimated to be 4.3%.2 Valeant Pharmaceuticals International, Inc. Dr. Lipner has served on It is more common in older individuals, with an inci- the advisory board for Sandoz, a Novartis company. Correspondence: Shari R. Lipner, MD, PhD, Department of dence rate of 20% in those older than 60 years and 3 Dermatology, Weill Cornell Medical College, 1305 York Ave, 50% in those older than 70 years. Onychomycosis New York, NY 10021 ([email protected]) is more common in patients with diabetes and E16 CUTIS® WWW.CUTIS.COM Copyright Cutis 2016. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. Onychomycosis Treatments 1.9 to 2.8 times higher than the general population.4 preparation and negative fungal culture with a com- Dermatophytes are responsible for the majority of pletely normal appearance of the nail. Mycological cases of onychomycosis, particularly Trichophyton cure is defined as potassium hydroxide microscopy rubrum and Trichophyton mentagrophytes.5 and fungal culture negative. Clinical cure is stated as Onychomycosis is divided into different sub- 0% nail plate involvement but at times is reported as types based on clinical presentation, which in turn less than 5% and less than 10% involvement. are characterized by varying infecting organisms Terbinafine and itraconazole are the only US and prognoses. The subtypes of onychomycosis are Food and Drug Administration (FDA)–approved distal and lateral subungual (DLSO), proximal sub- systemic therapies, and ciclopirox, efinaconazole, ungual, superficial, endonyx, mixed pattern, total and tavaborole are the only FDA-approved topicals. dystrophic, and secondary. Distal and lateral sub- Advantages of systemic agents generally are higher ungual onychomycosis are by far the most com- cure rates and shorter treatment courses, thus better mon presentation and begins when the infecting compliance. Disadvantages include greater inci- organism invades the hyponychium and distal or dence of systemic side effects and drug-drug interac- lateral nail bed. Trichophyton rubrum is the most com- tions as well as the need for laboratory monitoring. mon organism and T mentagrophytes is second, but Pros of topical therapies are low potential for adverse Candida parapsilosis and Candida albicans also are effects, no drug-drug interactions, and no monitor- possibilities. Proximal subungual onychomycosis is ing of blood work. Cons include lower efficacy, long far less frequent than DLSO and is usually caused treatment courses, and poor patient compliance. by T rubrum. The fungus invades the proximal nail Terbinafine, an allylamine, taken orally once folds and penetrates the newly growing nail plate.6 daily (250 mg) for 12 weeks for toenails and 6 weeks This pattern is more common in immunosuppressed for fingernails copycurrently is the preferred systemic patients and should prompt testing for human immu- treatment of onychomycosis, with complete cure nodeficiency virus.7 Total dystrophic onychomycosis rates of 38% and 59% and mycological cure rates of is the end stage of fungal nail plate invasion, may 70% and 79% for toenails and fingernails, respec- follow DLSO or proximal subungual onychomycosis, tively.not12 Itraconazole, an azole, is dosed orally at and is difficult to treat.6 200 mg daily for 3 months for toenails, with a Onychomycosis causes pain, paresthesia, and dif- complete cure rate of 14% and mycological cure ficulty with ambulation.8 In patients with peripheral rate of 54%.13 For fingernail onychomycosis only, neuropathy and vascular problems, including Dodia- itraconazole is dosed at 200 mg twice daily for betes, onychomycosis can increase the risk for foot 1 week, followed by a treatment-free period of ulcers, with amputation in severe cases.9 Patients 3 weeks, and then another 1-week course at the also may present with aesthetic concerns that may same dose. The complete cure rate is 47% and the impact their quality of life.10 mycological cure is 61% for this pulse regimen.13 Given the effect on quality of life along with Ciclopirox is a hydroxypyridone and the 8% nail medical risks associated with onychomycosis, a safe lacquer formulation was approved in 1999, making and successful treatment modality with a low risk it the first topical medication to gain FDA approval of recurrence is desirable. CUTISUnfortunately, treatment for the treatment of toenail onychomycosis. Based of nail fungus is quite challenging for a number of on 2 clinical trials, complete cure rates for toenails reasons. First, the thickness of the nail and/or the are 5.5% and 8.5% and mycological cure rates are fungal mass may be a barrier to the delivery of topi- 29% and 36% at 48 weeks with removal of residual cal and systemic drugs at the source of the infection. lacquer and debridement.14 Efinaconazole is an azole In addition, the nail plate does not have intrinsic and the 10% solution was FDA approved for the immunity. Also, recurrence after treatment is com- treatment of toenail onychomycosis in 2014.15 In mon due to residual hyphae or spores that were not 2 clinical trials, complete cure rates were 17.8% previously eliminated.11 Finally, many topical medi- and 15.2% and mycological cure rates were 55.2% cations require long treatment courses, which may and 53.4% with once daily toenail application for limit patient compliance, especially in patients who 48 weeks.16 Tavaborole is a benzoxaborole and the want to use nail polish for cosmesis or camouflage. 5% solution also was approved for the treatment of toenail onychomycosis in 2014.17 Two clinical trials Currently Approved Therapies reported complete cure rates of 6.5% and 9.1% and for Onychomycosis mycological cure rates of 31.1% and 35.9% with Several definitions are needed to better interpret the once daily toenail application for 48 weeks.18 results of onychomycosis clinical trials. Complete Given the poor efficacy, systemic side effects, cure is defined as a negative potassium hydroxide potential for drug-drug interactions, long-term WWW.CUTIS.COM VOLUME 98, NOVEMBER 2016 E17 Copyright Cutis 2016. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. Onychomycosis Treatments treatment courses, and cost associated with cur- efficacy (P<.001). This study showed that TTO, rent systemic and/or topical treatments, there has particularly TTO-NC, was effective in inhibiting been a renewed interest in natural remedies and the growth of T rubrum in vitro and that using nano- over-the-counter (OTC) therapies for onychomyco- capsule technology may increase nail penetration sis. This review summarizes the in vitro and in vivo and bioavailability.31 data, mechanisms of action, and clinical efficacy of Much of what we know about TTO’s antifun- various natural and OTC agents for the treatment gal mechanism of action comes from experiments of onychomycosis. Specifically, we summarize the involving C albicans. To date, it has not been studied data on tea tree oil (TTO), a popular topical cough in T rubrum or T mentagrophytes, the 2 most com- suppressant (TCS), natural coniferous resin (NCR) mon etiologies of onychomycosis.5 In C albicans, lacquer, Ageratina pichinchensis (AP) extract, and TTO causes altered permeability of plasma mem- ozonized sunflower oil.
Load more

Recommended publications
  • Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
    animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions.
    [Show full text]
  • New Insights Into the Effect of Amorolfine Nail Lacquer
    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
    [Show full text]
  • Evaluation of the Efficacy and Safety of Tavaborole Topical Solution, 5%, In
    Journal of Dermatological Treatment ISSN: 0954-6634 (Print) 1471-1753 (Online) Journal homepage: http://www.tandfonline.com/loi/ijdt20 Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich To cite this article: Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich (2017): Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2017.1329510 To link to this article: http://dx.doi.org/10.1080/09546634.2017.1329510 Accepted author version posted online: 18 May 2017. Published online: 30 May 2017. Submit your article to this journal Article views: 41 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ijdt20 Download by: [Oregon Health & Science University Library] Date: 27 September 2017, At: 13:42 JOURNAL OF DERMATOLOGICAL TREATMENT, 2017 https://doi.org/10.1080/09546634.2017.1329510 ORIGINAL ARTICLE Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,755,550 Shuman Et Al
    United States Patent (19) 11 Patent Number: 4,755,550 Shuman et al. (45) Date of Patent: Jul. 5, 1988 (54 READHERING AND REMOVABLE 56 References Cited ADHESIVE U.S. PATENT DOCUMENTS 4,644,026 2/1987 Shuman et al. .. ... 524/270 (75) Inventors: Ralph J. Shuman, Needham; Barbara 4,657,960 4/1987 Shuman et al. .. ... 524/270 Burns, Auburn, both of Mass. 4,684,685 8/1987 Shuman et al. ..................... 524/270 73) Assignee: Dennison Manufacturing Company, Primary Examiner-Ronald W. Griffin Framingham, Mass. Attorney, Agent, or Firm-Barry D. Josephs 57 ABSTRACT *) Notice: The portion of the term of this patent Agelled solid adhesive for coating substrates, typically subsequent to Feb. 17, 2004 has been paper. The adhesive can be made available in stick form disclaimed. and is easily applied in even coats to any surface area of the substrate. The adhesive has sufficient tack enabling the coated substrate to instantly adhere to essentially (21) Appl. No.: 29,031 any free contact surface upon gently pressing the sub strate to the free surface. The adhesive coated substrate (22 Filed: Mar. 23, 1987 is easily removable from the contact surface by manu ally lifting it thereform. The adhesive permits readher ence of the adhesive coated substrate to the same or Related U.S. Application Data different free contact surfaces. An adhesive coated 63 Continuation of Ser. No. 900, 112, Aug. 25, 1986, Pat. paper substrate will readhere many times to free paper No. 4,684,685, which is a continuation-in-part of Ser. contact surface. The preferred gelled adhesive product No.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 OFFICE DIRECTOR MEMO Deputy Office Director Decisional Memo Page 2 of 17 NDA 204,684 Miltefosine Capsules 1. Introduction Leishmania organisms are intracellular protozoan parasites that are transmitted to a mammalian host by the bite of the female phlebotomine sandfly. The main clinical syndromes are visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucosal leishmaniasis (ML). VL is the result of systemic infection and is progressive over months or years. Clinical manifestations include fever, hepatomegaly, splenomegaly, and bone marrow involvement with pancytopenia. VL is fatal if untreated. Liposomal amphotericin B (AmBisome®) was FDA approved in 1997 for the treatment of VL. CL usually presents as one or more skin ulcers at the site of the sandfly bite. In most cases, the ulcer spontaneously resolves within several months, leaving a scar. The goals of therapy are to accelerate healing, decrease morbidity and decrease the risk of relapse, local dissemination, or mucosal dissemination. There are no FDA approved drugs for the treatment of CL. Rarely, CL disseminates from the skin to the naso-oropharyngeal mucosa, resulting in ML. ML can also develop some time after CL spontaneous ulcer healing. The risk of ML is thought to be highest with CL caused by the subgenus Viannia. ML is characterized in the medical literature as progressive with destruction of nasal and pharyngeal structures, and death may occur due to complicating aspiration pneumonia. There are no FDA approved drugs for the treatment of ML. Paladin Therapeutics submitted NDA 204, 684 seeking approval of miltefosine for the treatment of VL caused by L.
    [Show full text]
  • Terbinafine-Induced Taste Impairment - Report of Two Cases Rajesh Sinha, Pallavi Sharma, Pramod Kumar, Vaibhav Kuchhal*
    Journal of Pakistan Association of Dermatologists 2012; 22 (4):363-365. Case Report Terbinafine-induced taste impairment - report of two cases Rajesh Sinha, Pallavi Sharma, Pramod Kumar, Vaibhav Kuchhal* Department of Skin &V.D., Government Medical College, Haldwani 263139, Uttarakhand, India *Department of E.N.T., Government Medical College, Haldwani 263139, Uttarakhand, India Abstract Terbinafine is an oral antimycotic agent that belongs to the allylamine class. It was introduced in 1991 and is being widely used, both topically and systemically, to treat fungal infections. Nowadays oral terbinafine has become a commonly prescribed drug to treat finger- and toenail fungal infections because of relatively short duration of treatment compared to other oral antifungals like griseofulvin and fluconazole. The common side effects of this drug include nausea, abdominal pain, elevated transaminases and allergic reactions. Loss of taste sensation is a rare side effect occurring in patient taking oral form of this drug. PubMed search showed that very few cases of terbinafine- induced taste loss have been reported worldwide. We report a case series of two patients who complained of taste loss after taking terbinafine. Key words Terbinafine, ageusia. Introduction terbinafine that occurs in 0.6% to 2.8% of patients taking the drug. A low BMI, ageing Terbinafine is a widely prescribed oral and history of taste loss are considered risk antifungal agent. Its mode of action is by factors for developing taste loss due to inhibiting squalene epoxidase which converts terbinafine. squalene to lanosterol. With a decrease in lanosterol production, ergosterol production is Case report 1 also diminished, affecting fungal cell membrane synthesis and function.
    [Show full text]
  • Extracts and Tinctures of Cannabis
    WHO Expert Committee on Drug Dependence Critical Review …………….. Extracts and tinctures of cannabis This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • HMSA ASO Topical Antifungals Jublia (Efinaconazole) Kerydin (Tavaborole
    PA Request Criteria HMSA ASO Topical Antifungals This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 855-762-5207. Please contact CVS/Caremark at 855-240-0543 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Topical Antifungals. Patient Information Patient Name: Patient Phone: - - Patient ID: Patient Group No: Patient DOB: / / Prescribing Physician Physician Name: Physician - - Phone: Physician Fax: - - Physician Address: City, State, Zip: Drug Name (select from list of drugs shown) Jublia (efinaconazole) Kerydin (tavaborole) Oxiconazole Cream Oxistat Cream (oxiconazole) Quantity: ____________ Frequency: __________________ Strength: __________________ Route of Administration: _______________________ Expected Length of Therapy: _____________________ Diagnosis: ICD Code: __________________________________ Comments: _____________________________________________________ ______________________________________________________________________ ______________________________________________________________________ Please check the appropriate answer for each applicable question. 1. Is this a request for oxiconazole cream (Oxistat)? Y N 2. Is the requested drug being prescribed for any of the following: A) tinea corporis, B) tinea Y N cruris, C) tinea pedis, D) tinea versicolor? 3. Is the drug being prescribed for onychomycosis of the toenail(s) due to Trichophyton Y N rubrum and Trichophyton mentagrophytes? 4. Has the diagnosis been confirmed with a fungal diagnostic test (e.g., KOH preparation, Y N fungal culture, or nail biopsy)? I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.
    [Show full text]
  • Long-Term Effectiveness of Treatment with Terbinafine Vs Itraconazole in Onychomycosis a 5-Year Blinded Prospective Follow-Up Study
    STUDY Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis A 5-Year Blinded Prospective Follow-up Study Ba´rður Sigurgeirsson, MD, PhD; Jo´n H. O´ lafsson, MD, PhD; Jo´n þ. Steinsson, MD Carle Paul, MD; Stephan Billstein, MD; E. Glyn V. Evans, PhD Objective: To examine long-term cure and relapse rates microscopy and culture at the end of follow-up and no re- after treatment with continuous terbinafine and inter- quirement of second intervention treatment. Secondary ef- mittent itraconazole in onychomycosis. ficacy criteria included clinical cure without second inter- vention treatment and mycological and clinical relapse rates. Design: Long-term prospective follow-up study. Results: Median duration of follow-up was 54 months. Setting: Three centers in Iceland. At the end of the study, mycological cure without second intervention treatment was found in 34 (46%) of the 74 Subjects: The study population comprised 151 pa- terbinafine-treated subjects and 10 (13%) of the 77 itra- tients aged 18 to 75 years with a clinical and mycologi- conazole-treated subjects (PϽ.001). Mycological and clini- cal diagnosis of dermatophyte toenail onychomycosis. cal relapse rates were significantly higher in itraconazole- vs terbinafine-treated patients (53% vs 23% and 48% vs Interventions: In a double-blind, double-dummy study, 21%, respectively). Of the 72 patients who received sub- patients were randomized to receive either terbinafine (250 sequent terbinafine treatment, 63 (88%) achieved myco- mg/d) for 12 or 16 weeks or itraconazole (400 mg/d) for logical cure and 55 (76%) achieved clinical cure. 1 week in every 4 for 12 or 16 weeks (first intervention).
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Rosin-Modified Phenolic Resin Compositions and Their Production
    Europaisches Patentamt 0 041 838 ® ê European Patent Office ® Publication number: Office européen des brevets B1 EUROPEAN PATENT SPECIFICATION ® Date of publication of patent spécification: 05.02.86 © Intel.4: C 08 G 8/34, C 08 L 61/14, C 09 D 11/10 (§) Application number: 81302492.4 (S) Date offiling: 04.06.81 (54) Rosin-modified phenolic resin compositions and their production. (§) Priority: 05.06.80 JP 74920/80 (§) Proprietor: DAINIPPON INK AND CHEMICALS, 30.09.80 JP 135184/80 INC. 30.09.80 JP 135185/80 35-58, Sakashita 3-chome 30.09.80 JP 135186/80 Itabashi-ku, Tokyo 174 (JP) (43) Dateof publication of application: (72) Inventor: Homma, Minoru 16.12.81 Bulletin 81/50 3-9-7 Kurosunadai Chiba-shi Chiba-ken (JP) Inventor: Kudo, Kin-ichi (§) Publication of the grant of the patent: c/o Mr. Muramatsu 2-21-8 Matsunami-cho 05.02.86 Bulletin 86/06 Chiba-shi Chiba-ken (JP) Inventor: Okoshi, Noboru 5-3-2-305 Masago (H) Designated Contracting States: Chiba-shi Chiba-ken (JP) DEFRGB Inventor: Shimoyama, Shoichi 3-6-14 Tsubakimori-cho Chiba-shi Chiba-ken (JP) (§) References cited.: . Inventor: Tashiro, Nansei DE-A-2 549 902 2848-100 Kubota 0Q DE-C- 831 323 Sodegaura-machi Kimitsu-gun Chiba-ken (JP) FR-A- 693 899 00 GB-A-486341 C0 @ Representative: Myerscough, Philip Boyd et al 00 J.A. Kemp & Co. 14, South Square Gray's Inn London, WC1R5EU (GB) The file contains technical information submitted after the application was filed and o not included in this specification o Note: Within nine monthsfrom the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]